item management s discussion and analysis of financial condition and results of operations except for the historical information contained herein  the following discussion contains forward looking statements that involve risks and uncertainties  including statements regarding the period of time during which the company s existing capital resources and income from various sources will be adequate to satisfy its capital requirements 
the company s actual results could differ materially from those discussed herein 
factors that could cause or contribute to such differences include  but are not limited to  those discussed in this section  as well as in the sections entitled business  licenses  manufacturing  sales and marketing  competition  government regulation  patents and proprietary rights  those discussed in the s registration statement file no 
filed with us securities and exchange commission  as well as those discussed in any documents incorporated by reference herein or therein 
the company was founded in  commenced its research and development activities in  completed an initial public offering the ipo in november  commenced clinical trials in december  acquired two fda cleared products  glofil and inulin  the acquisitions in august  and acquired a third fda cleared product  ethamolin  in november the company has sustained an accumulated deficit of  from inception through july  as the company will not have significant positive net operating cash flow for the next few years and the company s research and development  clinical testing and regulatory  sales and marketing and general and administrative expenses during these years will be substantial and increasing  the company expects to incur increasing losses for the foreseeable future 
results of operations year ended july  compared to year ended july  during the fiscal year ended july   the company sustained a loss of  or 
per share compared to a loss of  or 
per share for the prior fiscal year 
the gross profit of  on sales of glofil  inulin and ethamolin and other income of  principally interest income during the current fiscal year were offset by  in expenses in the sales and marketing  general and administrative  clinical testing and regulatory and research and development areas and  in amortization of discount and costs on its mandatorily convertible notes the notes 
during the prior fiscal year  the gross profit of  on sales of glofil and inulin and other income of  principally interest income was offset by  in expenses in the sales and marketing  general and administrative  clinical testing and regulatory and research and development areas and depreciation and amortization expenses 
sales and marketing expense increased by to  from  in the prior year  principally as a result of increased payroll expense from the hiring of additional field sales representatives  a product manager and an administrative assistant  and related travel  hotel and meal costs 
general and administrative expense increased by to  from  in the prior year 
of the increase was due to the commencement of a comprehensive investor relations program and the remainder reflected the impact of the expansion of the company s activities on personnel  consulting  business development  investment banking  rent  travel and meals  legal and accounting fees and insurance 
clinical testing and regulatory expense increased to  from  in the prior year  principally as the result of increased site costs and use of data input and management  statistical and other consultants to accelerate  finish and report on the company s various clinical trials 
depreciation and amortization expense increased to  from  in the prior year  principally as a result of the acquisition of ethamolin during the current year and the related amortization of that purchased technology 
during the current year  the company recognized  of expense related to the amortization of i the discount on the notes and ii the deferred financing costs related to the private placements of the notes 
this resulted from the re classification of the notes from equity to debt resulting from a review of the company s various filings under the securities exchange act of by the securities and exchange commission triggered by the filing of a registration statement during the year pertaining to the resale of the common stock underlying some of the notes 
year ended july  compared to year ended july  during the fiscal year ended july   the company sustained a loss of  or 
per share compared to a loss of  or 
per share for the prior fiscal year 
the gross profit of  on sales of glofil and inulin and other income of  principally interest income during the current fiscal year was offset by  in expenses in the sales and marketing  general and administrative  clinical testing and regulatory and research and development areas 
during the prior fiscal year  there were no product sales and other income of  principally interest income was offset by  in expenses in the above areas 
during the current year  the company spent  on sales and marketing  principally in the hiring of a field sales force and a customer service function and in various marketing and promotional programs 
no such expense was recorded in the prior fiscal year as the company was still in the development stage and had not yet acquired glofil and inulin 
clinical testing and regulatory expense decreased to  from  in the prior year  principally due to a decrease of  in contract research organization costs because of a lower accrual for the company s phase ii congestive heart failure trial on cpc and a decrease of  in licensing milestone expenses  offsetting increases in other areas  including a  increase in salary expense due to additional hiring 
during the prior year  the company recorded a one time milestone expense from the issuance of a non qualified stock option grant to the licensor of ceresine as a milestone payment for the completion of a phase i trial 
research and development expense increased to  from  in the prior year due to increases in salary expense  the use of outside collaborators and expense related to the phase ii small business innovation research grant for the neuronal calcium channel blocker program which grant was completed during the year and the six month phase i small business innovation research grant for the cpc pro drug program which was awarded to the company during the current year 
depreciation and amortization expense increased to  from  in the prior year  principally as a result of the acquisition of glofil and inulin during the current year and the related amortization of that purchased technology 
in addition  net interest and other income for the current year increased to  from  in the prior year principally due to i the interest income from a larger investment portfolio as a result of the various private placements during the year described below in liquidity and capital resources and the class a warrant program also described below in liquidity and capital resources  which was not available for all of the prior year period because the program began in november and was completed in february and ii fees and interest earned on a loan that the company made during the current year to a financial advisor 
liquidity and capital resources the company has principally funded its activities to date through its initial public offering ipo in november  which raised  subsequent exercises of its redeemable class a warrants in and early  which raised  exercises by the underwriter of the ipo of its unit purchase options and the redeemable class a warrants within such options  which raised  three private placements of mandatorily convertible notes during july  which raised net proceeds of  the notes and the harvard placement 
during the year   in principal amount of the notes was converted into  shares of common stock  no par value  of the company 
at july   the company had cash  cash equivalents and short term investments of  compared to  at july  also  the company s working capital at july  declined to  from  at july   principally as a result of the issuance of the  promissory note to schwarz pharma as partial consideration for the acquisition of ethamolin  which is due and payable in november the company expects that its cash needs will increase significantly in future periods due to expansion of its research and development programs  increased clinical testing activity  growth of administrative  clinical and laboratory staff and their related equipment and space needs 
management believes that the company s working capital will be sufficient to fund the operations of the company for approximately months dependent  in part  on the timing of the commencement of each phase of the clinical trials on cpc and ceresine and the funding priorities that it gives its various research programs  the results of clinical tests and research programs  competing technological and market developments  the time and costs involved in obtaining regulatory approvals and in obtaining  maintaining and enforcing patents  the cost of product acquisitions and their resulting cash flows and other factors 
the company expects to seek additional funds through exercises of its currently outstanding options and warrants  public or private equity financings  collaborations or from other sources 
there can be no assurance that funds can be obtained on desirable terms or at all 
the company may seek to raise additional capital whenever conditions in the financial markets are favorable  even if the company does not have an immediate need for additional cash at that time 

